SCFAs can reduce the expression of peroxisome proliferator-activated receptor-γ (PPAR-γ), leading to the increased oxidative metabolism of the liver and adipose tissue, reduced body fat accumulation, and hepatic steatosis, as well as increased insulin sensitivity. Here, PPARG is linked to fatty liver disease.